Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Commercialization Timeline Change

<< Previous

Bullboard Posts

Next >>

Comment by O12009on Feb 17, 2022 8:31pm

583 Views

Post# 34440319

RE:RE:RE:RE:RE:Commercialization Timeline Change

CancerSlayer wrote: Or, & more likely....the "commercialization phase" timeline (starting early 2023) may simply represent business planning/strategizing for a future commercial roll-out (I.e. feasibility, costs, price point, etc.) prior to actual market approval (projected to be mid-end of 2025).

In the past when we find out new information we always go back to prior news releases and there it is spelled out. So I don't think it's a mistake when they say January 2023 and they leave out that's with a partner. This should make for a fantastic news release.

<< Previous

Bullboard Posts

Next >>

How to trade on the stock market: A beginner’s guide